Search Results - "Kam, Boen L. R."

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls by Beukhof, Carolien M, Brabander, Tessa, van Nederveen, Francien H, van Velthuysen, Marie-Louise F, de Rijke, Yolanda B, Hofland, Leo J, Franssen, Gaston J H, Fröberg, Lideke A C, Kam, Boen L R, Visser, W Edward, de Herder, Wouter W, Peeters, Robin P

“…For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3-4 adverse…”
Get full text

Serum microRNA profiles in athyroid patients on and off levothyroxine therapy by Massolt, Elske T, Chaker, Layal, Visser, Theo J, Gillis, Ad J M, Dorssers, Lambert C J, Beukhof, Carolien M, Kam, Boen L R, Franssen, Gaston J, Brigante, Giulia, van Ginhoven, Tessa M, Visser, W Edward, Looijenga, Leendert H J, Peeters, Robin P

“…Levothyroxine replacement treatment in hypothyroidism is unable to restore physiological thyroxine and triiodothyronine concentrations in serum and tissues…”
Get full text

Long-Term Efficacy, Survival, and Safety of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors by Brabander, Tessa, van der Zwan, Wouter A, Teunissen, Jaap J M, Kam, Boen L R, Feelders, Richard A, de Herder, Wouter W, van Eijck, Casper H J, Franssen, Gaston J H, Krenning, Eric P, Kwekkeboom, Dik J

“…Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell…”
Get full text

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate by de Keizer, Bart, van Aken, Maarten O., Feelders, Richard A., de Herder, Wouter W., Kam, Boen L. R., van Essen, Martijn, Krenning, Eric P., Kwekkeboom, Dik J.

“…Introduction Receptor radionuclide therapy is a promising treatment modality for patients with neuroendocrine tumors for whom alternative treatments are…”
Get full text

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial) by Braat, Arthur J. A. T, Kwekkeboom, Dik J, Kam, Boen L. R, Teunissen, Jaap J. M, de Herder, Wouter W, Dreijerink, Koen M. A, van Rooij, Rob, Krijger, Gerard C, de Jong, Hugo W. A. M, van den Bosch, Maurice A. A. J, Lam, Marnix G. E. H

“…Background Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a…”
Get full text

Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate by van Vliet, Esther I., de Herder, Wouter W., de Rijke, Yolanda B., Zillikens, M. Carola, Kam, Boen L. R., Teunissen, Jaap J. M., Peeters, Robin P., Krenning, Eric P., Kwekkeboom, Dik J.

“…Purpose The aim of this study was to explore the possible mechanisms involved in an observed decline in serum calcium levels in patients with a neuroendocrine…”
Get full text

Peptide-receptor radionuclide therapy for endocrine tumors by van Essen, Martijn, Krenning, Eric P, Kam, Boen L. R, de Jong, Marion, Valkema, Roelf, Kwekkeboom, Dik J

“…Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, such as octreotide, is a promising option for the treatment of…”
Get full text

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study by Kloth, Jacqueline S. L., Klümpen, Heinz-Josef, Yu, Huixin, Eechoute, Karel, Samer, Caroline F., Kam, Boen L. R., Huitema, Alwin D. R., Daali, Youssef, Zwinderman, Aeilko H., Balakrishnar, Bavanthi, Bennink, Roelof J., Wong, Mark, Schellens, Jan H. M., Mathijssen, Ron H. J., Gurney, Howard

“…Background and Objective The wide inter-patient variability in drug exposure partly explains the toxicity and efficacy profile of sunitinib treatment. In this…”
Get full text

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy by van Vliet, Esther I, Teunissen, Jaap J M, Kam, Boen L R, de Jong, Marion, Krenning, Eric P, Kwekkeboom, Dik J

“…The primary treatment of gastroenteropancreatic neuroendocrine tumors (GEPNETs) is surgery with curative intent or debulking of the tumor mass. In case of…”
Get more information

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs by Bergsma, Hendrik, MD, PhD, van Vliet, Esther I., MD, PhD, Teunissen, Jaap J.M., MD, PhD, Kam, Boen L.R., MD, de Herder, Wouter W., MD, PhD, Peeters, Robin P., MD, PhD, Krenning, Eric P., MD, PhD, Kwekkeboom, Dik J., MD, PhD

“…Abstract Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with…”
Get full text

[(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy by Pool, Stefan E, Kam, Boen L R, Koning, Gerben A, Konijnenberg, Mark, Ten Hagen, Timo L M, Breeman, Woulter A P, Krenning, Eric P, de Jong, Marion, van Eijck, Casper H J

“…With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we…”
Get more information

Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer by Simons, Janine M, van Nijnatten, Thiemo J A, van der Pol, Carmen C, van Diest, Paul J, Jager, Agnes, van Klaveren, David, Kam, Boen L R, Lobbes, Marc B I, de Boer, Maaike, Verhoef, Cees, Sars, Paul R A, Heijmans, Harald J, van Haaren, Els R M, Vles, Wouter J, Contant, Caroline M E, Menke-Pluijmers, Marian B E, Smit, Léonie H M, Kelder, Wendy, Boskamp, Marike, Koppert, Linetta B, Luiten, Ernest J T, Smidt, Marjolein L

“…Several less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients…”
Get more information

Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer by van Velsen, Evert F S, Stegenga, Merel T, van Kemenade, Folkert J, Kam, Boen L R, van Ginhoven, Tessa M, Visser, W Edward, Peeters, Robin P

“…Recently, the eighth edition of the American Joint Committee on Cancer (AJCC)/tumor node metastasis (TNM) staging system for differentiated thyroid cancer…”
Get more information

Longitudinal analysis of quality of life in patients treated for differentiated thyroid cancer by van Velsen, Evert F S, Massolt, Elske T, Heersema, Hélène, Kam, Boen L R, van Ginhoven, Tessa M, Visser, W Edward, Peeters, Robin P

“…Objective Earlier cross-sectional studies showed that patients with differentiated thyroid cancer (DTC) have a significant reduction of quality of life (QoL)…”
Get full text

A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study by van Nijnatten, Thiemo J.A, Simons, Janine M, Smidt, Marjolein L, van der Pol, Carmen C, van Diest, Paul J, Jager, Agnes, van Klaveren, David, Kam, Boen L.R, Lobbes, Marc B.I, de Boer, Maaike, Verhoef, Kees, Koppert, Linetta B, Luiten, Ernest J.T

“…Abstract Background In 1 of 3 patients with initial lymph node-positive (cN+ ) breast cancer, neoadjuvant chemotherapy (NAC) results in an axillary pathologic…”
Get full text

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate by Brabander, Tessa, van der Zwan, Wouter A, Teunissen, Jaap J M, Kam, Boen L R, de Herder, Wouter W, Feelders, Richard A, Krenning, Eric P, Kwekkeboom, Dik J

“…Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic…”
Get full text

Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer by van Velsen, Evert F S, Stegenga, Merel T, van Kemenade, Folkert J, Kam, Boen L R, van Ginhoven, Tessa M, Visser, W Edward, Peeters, Robin P

“…Abstract Context Current American Thyroid Association (ATA) Management Guidelines for the treatment of differentiated thyroid cancer (DTC) stratify patients to…”
Get full text

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors by Zandee, Wouter T, Brabander, Tessa, Blažević, Anela, Kam, Boen L R, Teunissen, Jaap J M, Feelders, Richard A, Hofland, Johannes, de Herder, Wouter W

“…Abstract Purpose Peptide receptor radionuclide therapy (PRRT) with the radiolabeled somatostatin analogue [Lutetium-177-DOTA0-Tyr3]octreotate (177Lu-DOTATATE)…”
Get full text

Thyroid State Regulates Gene Expression in Human Whole Blood by Massolt, Elske T, Meima, Marcel E, Swagemakers, Sigrid M A, Leeuwenburgh, Selmar, van den Hout-van Vroonhoven, Mirjam C G M, Brigante, Giulia, Kam, Boen L R, van der Spek, Peter J, van IJcken, Wilfred F J, Visser, Theo J, Peeters, Robin P, Visser, W Edward

“…Despite the well-recognized clinical features resulting from insufficient or excessive thyroid hormone (TH) levels in humans, it is largely unknown which genes…”
Get full text

Pressure‐volume analysis in athyroid patients off and on thyroxine supplementation: a pilot study by B. Bastos, Marcelo, Massolt, Elske T., Kam, Boen L. R., Peeters, Robin P., Van Mieghem, Nicolas M., Visser, W. Edward, Uil, Corstiaan A.

“…Thyroid hormone importantly affects the cardiovascular system. However, evaluation of stroke volume (SV) and its determinants is confounded by variations in…”
Get full text